AR121573A1 - Moduladores de nlrp3 - Google Patents
Moduladores de nlrp3Info
- Publication number
- AR121573A1 AR121573A1 ARP210100650A ARP210100650A AR121573A1 AR 121573 A1 AR121573 A1 AR 121573A1 AR P210100650 A ARP210100650 A AR P210100650A AR P210100650 A ARP210100650 A AR P210100650A AR 121573 A1 AR121573 A1 AR 121573A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- haloalkyl
- halogen
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Amplifiers (AREA)
- Burglar Alarm Systems (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) o una sal o solvato farmacéuticamente aceptable de este, caracterizado por que: X¹ es O, S o N(R³); X² es -N(R⁴)- o -C(R⁴)₂-; X³ es -N(R⁵)- o -C(R⁵)₂-; Y¹ es O, S o N(R⁸); Y² es N o C(R⁹); Z¹ es O, S, N(R³), o -C(R¹⁷)=C(R¹⁷)-; Z² es N o C(R¹⁹); R¹ es un compuesto del grupo de fórmulas (2); R² es un compuesto del grupo de fórmulas (3); R³ es hidrógeno, -OR¹⁴, -CN, -NO₂ o -S(=O)₂R¹⁵; cada R⁴ se selecciona independientemente de hidrógeno, alquilo C₁₋₆, alquilo -C₁₋₆-OR⁷ y alquilo -C₁₋₆-N(R⁷)₂; cada R⁵ se selecciona independientemente de hidrógeno, alquilo C₁₋₆, alquilo -C₁₋₆-OR⁷ y alquilo -C₁₋₆-N(R⁷)₂; cada R⁶ se selecciona independientemente de alquilo C₁₋₆, alquilo -C₁₋₆-CO₂R¹⁸, haloalquilo C₁₋₆, alquilo -C₁₋₆-OR⁷ y alquilo C₁₋₆-N(R⁷)₂; cada R⁷ se selecciona de independientemente de hidrógeno y alquilo C₁₋₆; R⁸ es hidrógeno, alquilo C₁₋₆, alquilo -C₁₋₆-OR⁷, alquilo -C₁₋₆-N(R⁷)₂ o cicloalquilo C₃₋₆; R⁹ es hidrógeno, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆ y cicloalquilo C₃₋₆; R¹⁰ es hidrógeno, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alquilo -C₁₋₆-OR⁷ o alquilo -C₁₋₆-N(R⁷)₂; R¹¹ y R¹² se seleccionan independientemente de hidrógeno, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alquilo -C₁₋₆-OR⁷ y alquilo C₁₋₆-N(R⁷)₂; o R¹¹ y R¹² se combinan para formar un anillo cicloalquilo de 5 ó 6 miembros; R¹³ es hidrógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₅, heterocicloalquilo C₂₋₉, fenilo o heteroarilo C₂₋₉, donde el cicloalquilo C₃₋₅, heterocicloalquilo C₂₋₉, fenilo y heteroarilo C₂₋₉ están opcionalmente sustituidos con 1, 2, 3 ó 4 R¹⁶; R¹⁴ es hidrógeno o alquilo C₁₋₆; R¹⁵ es alquilo C₁₋₆; o cada R¹⁶ se selecciona independientemente de halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, cicloalquilo C₃₋₆, heterocicloalquilo C₂₋₉, arilo C₆₋₁₀, heteroarilo C₂₋₉, donde el cicloalquilo C₃₋₆, heterocicloalquilo C₂₋₉, arilo C₆₋₁₀ y el heteroarilo C₂₋₉ están opcionalmente sustituidos con 1, 2 ó 3 grupos seleccionados entre halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆ y haloalcoxi C₁₋₆; cada R¹⁷ se selecciona independientemente de hidrógeno, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alquilo -C₁₋₆-OR⁷ y alquilo -C₁₋₆-N(R⁷)₂; R¹⁸ es hidrógeno o alquilo C₁₋₆; R¹⁹ es hidrógeno, halógeno, -CN, alquilo C₁₋₆, haloalquilo C₁₋₆, alquilo -C₁₋₆-OR⁷ o alquilo -C₁₋₆-N(R⁷)₂; m es 0, 1 ó 2; n es 1, 2 ó 3; p es 0, 1 ó 2; q es 0, 1, 2, 3 ó 4; s es 1, 2 ó 3; y t es 1, 2 ó 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062990363P | 2020-03-16 | 2020-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121573A1 true AR121573A1 (es) | 2022-06-15 |
Family
ID=77747550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100650A AR121573A1 (es) | 2020-03-16 | 2021-03-15 | Moduladores de nlrp3 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11603375B2 (es) |
| EP (1) | EP4121059A4 (es) |
| JP (1) | JP2023518044A (es) |
| KR (1) | KR20220154165A (es) |
| CN (1) | CN115605209A (es) |
| AR (1) | AR121573A1 (es) |
| AU (1) | AU2021237477A1 (es) |
| BR (1) | BR112022018480A2 (es) |
| CA (1) | CA3175729A1 (es) |
| CL (1) | CL2022002531A1 (es) |
| CO (1) | CO2022014499A2 (es) |
| IL (1) | IL296488A (es) |
| MX (1) | MX2022011576A (es) |
| TW (1) | TW202200584A (es) |
| WO (1) | WO2021188450A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023518044A (ja) | 2020-03-16 | 2023-04-27 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| WO2022171185A1 (zh) * | 2021-02-10 | 2022-08-18 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3888749A1 (en) | 2015-02-16 | 2021-10-06 | The University of Queensland | Sulfonylureas and related compounds and use of same |
| MA44225A (fr) | 2016-02-16 | 2018-12-26 | The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv | Sulfonylurées et composés apparentés et leur utilisation |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| CR20190356A (es) * | 2017-01-23 | 2019-11-20 | Genentech Inc | Compuestos químicos como inhibidores de la actividad de la interleuquina-1 |
| WO2018215818A1 (en) * | 2017-05-24 | 2018-11-29 | The University Of Queensland | Novel compounds and uses |
| PL3661925T3 (pl) * | 2017-07-07 | 2022-02-28 | Inflazome Limited | Nowe związki sulfonamidowo karboksyamidowe |
| CN111093773A (zh) | 2017-08-15 | 2020-05-01 | 英夫拉索姆有限公司 | 作为nlrp3抑制剂的磺酰脲和磺酰硫脲 |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| WO2019079119A1 (en) | 2017-10-17 | 2019-04-25 | IFM Tre, Inc. | SULFONAMIDES AND ASSOCIATED COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| AU2019306658A1 (en) | 2018-07-20 | 2021-01-07 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| WO2020086732A1 (en) | 2018-10-24 | 2020-04-30 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| KR20220066254A (ko) | 2019-07-17 | 2022-05-24 | 조마젠 바이오사이언시즈 엘티디 | Nlrp3 조절제 |
| EP3999496A1 (en) | 2019-07-17 | 2022-05-25 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as nlpr3 modulators for the treatment of multiple sclerosis (ms) |
| JP2023518044A (ja) | 2020-03-16 | 2023-04-27 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
-
2021
- 2021-03-15 JP JP2022555714A patent/JP2023518044A/ja active Pending
- 2021-03-15 WO PCT/US2021/022397 patent/WO2021188450A1/en unknown
- 2021-03-15 MX MX2022011576A patent/MX2022011576A/es unknown
- 2021-03-15 KR KR1020227035334A patent/KR20220154165A/ko active Search and Examination
- 2021-03-15 EP EP21770604.3A patent/EP4121059A4/en active Pending
- 2021-03-15 US US17/202,047 patent/US11603375B2/en active Active
- 2021-03-15 CN CN202180035570.2A patent/CN115605209A/zh active Pending
- 2021-03-15 CA CA3175729A patent/CA3175729A1/en active Pending
- 2021-03-15 AU AU2021237477A patent/AU2021237477A1/en active Pending
- 2021-03-15 BR BR112022018480A patent/BR112022018480A2/pt not_active Application Discontinuation
- 2021-03-15 AR ARP210100650A patent/AR121573A1/es unknown
- 2021-03-15 IL IL296488A patent/IL296488A/en unknown
- 2021-03-16 TW TW110109276A patent/TW202200584A/zh unknown
-
2022
- 2022-09-15 CL CL2022002531A patent/CL2022002531A1/es unknown
- 2022-10-12 CO CONC2022/0014499A patent/CO2022014499A2/es unknown
-
2023
- 2023-02-02 US US18/163,680 patent/US20230183258A1/en not_active Abandoned
- 2023-10-09 US US18/483,397 patent/US20240101571A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220154165A (ko) | 2022-11-21 |
| CN115605209A (zh) | 2023-01-13 |
| AU2021237477A1 (en) | 2022-10-13 |
| US20210292336A1 (en) | 2021-09-23 |
| CL2022002531A1 (es) | 2023-03-31 |
| EP4121059A1 (en) | 2023-01-25 |
| US20240101571A1 (en) | 2024-03-28 |
| IL296488A (en) | 2022-11-01 |
| BR112022018480A2 (pt) | 2022-11-29 |
| TW202200584A (zh) | 2022-01-01 |
| CA3175729A1 (en) | 2021-09-23 |
| JP2023518044A (ja) | 2023-04-27 |
| WO2021188450A1 (en) | 2021-09-23 |
| US20230183258A1 (en) | 2023-06-15 |
| CO2022014499A2 (es) | 2023-02-16 |
| US11603375B2 (en) | 2023-03-14 |
| EP4121059A4 (en) | 2023-12-13 |
| MX2022011576A (es) | 2022-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121573A1 (es) | Moduladores de nlrp3 | |
| AR088293A1 (es) | Inhibidores de proteina cinasa | |
| AR111284A1 (es) | Agonistas del receptor farnesoide x y usos de los mismos | |
| AR105104A1 (es) | Derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR123089A2 (es) | Compuesto de piridinona | |
| AR109974A2 (es) | Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes | |
| AR103182A1 (es) | Inmunomoduladores | |
| AR112907A1 (es) | Pirazoles inhibidores de monoacilglicerol lipasa (magl) | |
| AR098492A1 (es) | Derivados de purina | |
| AR107488A1 (es) | Compuestos de benzopirazol y análogos de éstos | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR114421A1 (es) | Piperidinil-3-(ariloxi)-propanamidas y propanoatos | |
| AR089051A1 (es) | Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos | |
| AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR116424A1 (es) | Moduladores de la somatostatina y usos de los mismos | |
| AR113886A1 (es) | Derivados de indol macrocíclicos | |
| AR116464A1 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| AR096423A1 (es) | Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona | |
| AR096424A1 (es) | Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona | |
| AR105571A1 (es) | Compuestos reguladores del crecimiento vegetal | |
| AR119397A1 (es) | Compuestos herbicidas | |
| AR115898A1 (es) | 1,7-naftiridinas como inhibidores de cdk8/19 | |
| AR110936A1 (es) | COMPUESTOS DE INDOL PIPERIDINA CON ACTIVIDAD AGONISTA b ADRENÉRGICA Y ANTIMUSCARÍNICA |